Acadian Asset Management LLC Acquires New Position in ADMA Biologics, Inc. (NASDAQ:ADMA)

Acadian Asset Management LLC acquired a new stake in ADMA Biologics, Inc. (NASDAQ:ADMA) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 8,357 shares of the biotechnology company’s stock, valued at approximately $93,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. EntryPoint Capital LLC purchased a new stake in shares of ADMA Biologics in the first quarter valued at approximately $31,000. Simplicity Wealth LLC purchased a new stake in shares of ADMA Biologics during the 1st quarter worth $68,000. CWM LLC grew its stake in shares of ADMA Biologics by 114.2% during the 2nd quarter. CWM LLC now owns 8,192 shares of the biotechnology company’s stock worth $92,000 after purchasing an additional 4,367 shares during the period. Viewpoint Capital Management LLC increased its holdings in shares of ADMA Biologics by 18.6% in the 1st quarter. Viewpoint Capital Management LLC now owns 15,416 shares of the biotechnology company’s stock valued at $102,000 after purchasing an additional 2,416 shares in the last quarter. Finally, Eagle Asset Management Inc. lifted its stake in shares of ADMA Biologics by 20.2% in the fourth quarter. Eagle Asset Management Inc. now owns 25,957 shares of the biotechnology company’s stock valued at $117,000 after purchasing an additional 4,367 shares during the period. Institutional investors and hedge funds own 75.68% of the company’s stock.

ADMA Biologics Stock Performance

Shares of ADMA opened at $19.98 on Friday. ADMA Biologics, Inc. has a 12-month low of $3.06 and a 12-month high of $20.16. The stock has a market cap of $4.63 billion, a P/E ratio of -999.00 and a beta of 0.61. The company has a current ratio of 6.87, a quick ratio of 2.80 and a debt-to-equity ratio of 0.74. The company has a 50-day moving average of $15.77 and a two-hundred day moving average of $10.96.

ADMA Biologics (NASDAQ:ADMA) last issued its quarterly earnings data on Thursday, August 8th. The biotechnology company reported $0.13 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.08 by $0.05. The firm had revenue of $107.20 million during the quarter, compared to the consensus estimate of $86.44 million. ADMA Biologics had a return on equity of 38.79% and a net margin of 10.53%. The company’s quarterly revenue was up 78.4% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.02) EPS. As a group, research analysts predict that ADMA Biologics, Inc. will post 0.49 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on ADMA shares. Mizuho upped their target price on shares of ADMA Biologics from $12.00 to $14.00 and gave the stock a “buy” rating in a research report on Thursday, June 20th. HC Wainwright upped their price target on ADMA Biologics from $10.00 to $18.00 and gave the stock a “buy” rating in a report on Monday, August 12th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $20.00 price objective on shares of ADMA Biologics in a research note on Friday. One analyst has rated the stock with a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, ADMA Biologics has an average rating of “Buy” and a consensus target price of $15.50.

Insider Activity

In related news, Director Lawrence P. Guiheen sold 9,000 shares of ADMA Biologics stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $18.47, for a total transaction of $166,230.00. Following the completion of the sale, the director now owns 153,941 shares in the company, valued at approximately $2,843,290.27. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In other news, CEO Adam S. Grossman sold 236,889 shares of the business’s stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $17.69, for a total value of $4,190,566.41. Following the completion of the transaction, the chief executive officer now owns 2,059,726 shares of the company’s stock, valued at $36,436,552.94. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Lawrence P. Guiheen sold 9,000 shares of the company’s stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $18.47, for a total transaction of $166,230.00. Following the transaction, the director now directly owns 153,941 shares in the company, valued at approximately $2,843,290.27. The disclosure for this sale can be found here. Insiders have sold 466,900 shares of company stock worth $8,224,121 over the last three months. 3.70% of the stock is currently owned by corporate insiders.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.